Thus, we chose the Myc-CaP and TRAMP-C2 transgenic prostate cancer cell lines as two common orthotopically implantable in vivo models differing generally in iron background due to their syngeneic FVB/N and C57BL/6 syngeneic mouse hosts50 in order to correlate the spatial distributions of iron deposits with systemic and anti-tumor response to chelation therapy in prostate cancer. The gene discussed is MYC; the disease is neoplasm.